FY2026 Earnings Forecast for AxoGen Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS forecast for AxoGen to a loss of $0.34 per share from a prior estimate of $0.46, while maintaining a Buy rating and a $56 price target.
• AxoGen reported quarterly EPS of $0.21, beating the $0.13 consensus estimate, and revenue of $75.83 million versus expectations of $73.45 million.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and $57.92 target price; institutional investors own 80.29% of the company, although insiders sold 98,503 shares last quarter.

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - HC Wainwright lifted their FY2026 earnings estimates for AxoGen in a report issued on Thursday, October 29th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will post earnings per share of ($0.34) for the year, up from their prior forecast of ($0.46). HC Wainwright currently has a "Buy" rating and a $56.00 price target on the stock. The consensus estimate for AxoGen's current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for AxoGen's Q4 2026 earnings at ($0.01) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.04 EPS, Q4 2027 earnings at $0.09 EPS and FY2027 earnings at $0.10 EPS.

AXGN has been the subject of several other research reports. Citizens Jmp increased their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a "market outperform" rating in a research report on Thursday, July 30th. Wells Fargo & Company lifted their price objective on shares of AxoGen from $48.00 to $56.00 and gave the stock an "overweight" rating in a research report on Thursday, October 29th. Wall Street Zen raised shares of AxoGen from a "hold" rating to a "strong-buy" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of AxoGen in a research note on Wednesday, August 26th. Finally, Citigroup reissued a "market outperform" rating on shares of AxoGen in a research report on Thursday, July 30th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AxoGen presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.92.

AxoGen Stock Up 1.0%

Shares of NASDAQ:AXGN opened at $49.85 on Tuesday. The company has a market capitalization of $2.68 billion, a PE ratio of -76.69 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. The business has a fifty day moving average price of $42.84 and a two-hundred day moving average price of $39.54. AxoGen has a 1 year low of $21.92 and a 1 year high of $52.91.

AxoGen (NASDAQ:AXGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, beating the consensus estimate of $0.13 by $0.08. The firm had revenue of $75.83 million during the quarter, compared to analyst estimates of $73.45 million. AxoGen had a negative net margin of 11.96% and a negative return on equity of 7.18%.

Insider Buying and Selling at AxoGen

In other news, Director Amy Wendell sold 13,353 shares of AxoGen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the completion of the transaction, the director directly owned 107,976 shares in the company, valued at approximately $5,228,197.92. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph A. Tyndall sold 3,500 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the sale, the director owned 10,650 shares in the company, valued at approximately $529,305. The trade was a 24.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 98,503 shares of company stock valued at $4,656,947 in the last quarter. Corporate insiders own 2.44% of the company's stock.

Institutional Investors Weigh In On AxoGen

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of AxoGen during the 2nd quarter worth $204,123,000. Artemis Investment Management LLP raised its position in AxoGen by 27.5% during the third quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider's stock valued at $74,659,000 after purchasing an additional 384,200 shares in the last quarter. Wellington Management Group LLP raised its position in AxoGen by 44.3% during the second quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider's stock valued at $64,280,000 after purchasing an additional 427,089 shares in the last quarter. Bamco Inc. NY bought a new stake in AxoGen during the second quarter worth about $34,190,000. Finally, TimesSquare Capital Management LLC bought a new position in shares of AxoGen during the 2nd quarter valued at about $31,863,000. 80.29% of the stock is currently owned by institutional investors.

About AxoGen

AxoGen, Inc NASDAQ: AXGN is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company's product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient's body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.